Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gilead Sciences : and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 10:25pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead's cash tender offer for Kite expired at 11:59 p.m. on September 25, 2017 (see also Biotechnology Companies).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170926005682/en/

On September 8, 2017, Gilead and Kite filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice.

Keywords for this news article include: Gilead Sciences Inc., Biotechnology Companies, Biopharmaceutical Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES -3.53% 72.92 Delayed Quote.1.79%
KITE PHARMA INC 0.00%-End-of-day quote.300.96%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08/17Bach proposes CAR T payment options for CMS
AQ
08/16GILEAD SCIENCES : Patent Issued for Use Of Solid Carrier Particles To Improve Th..
AQ
08/16GILEAD SCIENCES : "Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutic..
AQ
08/16GILEAD SCIENCES' : Trademark Application for "GILEAD HIVAGE POSITIVELY" Filed
AQ
08/16GILEAD SCIENCES : Report Summarizes Amino Acids Study Findings from Gilead Scien..
AQ
08/14GILEAD SCIENCES : Announces Executive Promotions
BU
08/10GILEAD SCIENCES : China National Drug Administration Approves Gilead's Genvoya, ..
AQ
08/09GILEAD SCIENCES : An Application for the Trademark "EMTAUGRIS" Has Been Filed by..
AQ
08/09GILEAD SCIENCES : An Application for the Trademark "RYMTACLI" Has Been Filed by ..
AQ
08/09GILEAD SCIENCES : Trademark Application for "OMPLIXIS" Filed by Gilead Sciences
AQ
More news
News from SeekingAlpha
08/18SANGAMO THERAPEUTICS : More Catalysts Powering A Gene-Based Innovator 
08/17Gilead continues selloff, down 3% 
08/16A Synopsis Of The HIV Market 
08/16PEPSICO AND GILEAD : 2 Very Different CEO Departures 
08/15Investors shun healthcare stocks in broad market selloff 
Financials ($)
Sales 2018 21 360 M
EBIT 2018 11 160 M
Net income 2018 6 650 M
Debt 2018 12 363 M
Yield 2018 3,12%
P/E ratio 2018 14,19
P/E ratio 2019 13,24
EV / Sales 2018 5,00x
EV / Sales 2019 4,95x
Capitalization 94 529 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 87,9 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Andrew Cheng Chief Medical Officer & Executive Vice President
John G. McHutchison Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.79%94 529
VERTEX PHARMACEUTICALS16.75%44 999
REGENERON PHARMACEUTICALS-1.11%39 726
NEUROCRINE BIOSCIENCES, INC.46.41%10 370
GENMAB2.28%9 923
SAREPTA THERAPEUTICS INC134.09%8 654